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Abstract: Mucormycosis is an invasive fungal infection characterised by rapid filamentous growth,
which leads to angioinvasion, thrombosis, and tissue necrosis. The high mortality rates (50–100%)
associated with mucormycosis are reflective of not only the aggressive nature of the infection and
the poor therapeutics currently employed, but also the failure of the human immune system to
successfully clear the infection. Immune effector interaction with Mucorales is influenced by the
developmental stage of the mucormycete spore. In a healthy immune environment, resting spores
are resistant to phagocytic killing. Contrarily, swollen spores and hyphae are susceptible to damage
and degradation by macrophages and neutrophils. Under the effects of immune suppression,
the recruitment and efficacy of macrophage and neutrophil activity against mucormycetes is
considerably reduced. Following penetration of the endothelial lining, Mucorales encounter platelets.
Platelets adhere to both mucormycete spores and hyphae, and exhibit germination suppression and
hyphal damage capacity in vitro. Dendritic cells are activated in response to Mucorales hyphae
only, and induce adaptive immunity. It is crucial to further knowledge regarding our immune
system’s failure to eradicate resting spores under intact immunity and inhibit fungal growth under
immunocompromised conditions, in order to understand mucormycosis pathogenicity and enhance
therapeutic strategies for mucormycosis.
Keywords: mucormycosis; spores; hyphae; innate immunity; macrophages; neutrophils; dendritic cells;
platelets; adaptive immunity
1. Introduction
There has been a stark increase in invasive fungal infections over the past two decades [1].
One such infection is mucormycosis, which is caused by species of the Mucorales order. Rhizopus,
Mucor and Lichtheimia spp. are responsible for the highest number of reported mucormycosis infections [2].
Rhizopus oryzae is the most common causative agent of mucormycosis, followed by Mucor circinelloides and
Lichtheimia corymbifera,which collectively account for around 70% of infections [2–6]. This life-threatening
invasive fungal infection carries an extortionate mortality rate, which is estimated at >95% in
those with disseminated disease [7]. With medical advances in immunosuppressive treatments
and transplantation surgeries, there has inevitably been an increase in the population at risk of
mucormycosis [5]. Mucorales commonly establish disease in those with immunocompromised
status, with notable pre-disposing risk factors including diabetes mellitus with ketoacidosis (DKA),
organ transplantation, chemotherapy, haematological diseases, and elevated serum iron levels [5,8].
The unacceptable high mortality rates associated with mucormycosis are reflective not only of the
aggressive nature of the infection and the poor therapeutics currently employed, but also the failure of
the human immune system to successfully clear infection. Disease establishment occurs rapidly
once filamentous growth has been initiated; it leads to angioinvasion (a hallmark of infection
enabling the haematogenous dissemination of disease), thrombosis, and tissue necrosis [9]. Currently,
the efficacy of anti-fungal therapeutics, namely liposomal amphotericin B and isavuconazole,
is poor (approx. 60–70%), which is pressing great urge on enhancing our current understanding of
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the Mucorales interaction with the host, in prospect of identifying novel drug targets or treatment
strategies [10].
2. The Innate Immune Response to Mucorales
Innate immunity is ‘non-specific’ and comprised of physical barriers such as the skin and
respiratory mucosa preventing microbial entrance to the host, complement proteins aiding recognition
by immune effector cells, and immune effector cells themselves acting in a complex network to combat
pathogenic invasion. Mucorales hold the ability to cross physical barriers, most namely the skin,
by means of trauma wounds, and the gut by means of ingestion [11–14]. In the case of pathogen
infiltration, the innate immune response acts to cease pathogenic spread, resists the establishment of
infection, and triggers the adaptive immune response. Following the successful crossing of physical
barriers, Mucorales encounter cells of the innate immune system, including macrophages, neutrophils,
and dendritic cells (DC). The ability of Mucorales to establish disease within the human host begins at
the failure of the innate immune system to kill fungal spores and halt fungal germination, thus ceasing
to limit the expansion of disease [5,15].
Immunosuppressive therapy impairs immune phagocytic effector functions and significantly
increases susceptibility to invasive mould infections. For example, macrophage depletion in the
zebrafish larvae Danio rerio by metronidazole treatment significantly accelerated disease progression
and increased mortality in response to Mucorales infection [16]. Likewise, alloxan treatment of
rabbits to induce diabetes with acidosis showed delayed leukocyte recruitment to dermal sites of
Rhizopus oryzae inoculation, an earlier germination of fungal spores, and wider spread of infection [17].
To optimise our understanding of Mucorales pathogenesis, it is necessary to understand the innate
immune response to mucormycetes both under immunocompetency and immunocompromisation.
2.1. Epithelial Interaction with Mucorales
The first line of defence against Mucorales are the epithelial cells that are encountered at the initial
sites of infection, such as alveoli and skin epithelia [18,19]. Patients at risk of invasive mucormycosis
exhibit epithelial damage that extends to the basement membrane and exposes extracellular matrix
proteins [18]. R. oryzae resting spores have been shown to adhere to the basement membrane
proteins laminin and type IV collagen [18]. Following adhesion to the basement membrane proteins,
Mucorales spores germinate and invade host cells. R. oryzae-specific genes encoding lytic enzymes are
expressed in those with invasive mucormycosis, which is perhaps indicative of the means of tissue
invasion by Mucorales [20].
2.2. Macrophage Response to Mucorales
The ability of macrophages to successfully interact with, engulf, degrade, and present pathogenic
antigens is key to not only localising infection in its early stages, but also priming the adaptive
immune response, which is far more aggressive and specific in the case of pathogenic re-encounter.
In order to identify mishaps in this process that may render immunocompromised individuals
susceptible to mucormycosis, it is essential to first understand the process under healthy immunity.
During germination, Mucorales sporangiospores exit a dormant, resting phase and undergo both
swelling in size and an increase in metabolic activity before commencing filamentous growth [21].
A recent study investigating the phagocytosis of resting spores, swollen spores, and opsonised spores
from virulent and attenuated Lichtheimia corymbifera strains by murine macrophages, found spores
from the virulent strain are more readily phagocytosed than the attenuated strain across all three
conditions [22]. Furthermore, resting and swollen spores of the virulent Lichtheimia strain were found
to be less readily phagocytosed than opsonised spores. Spores of the attenuated Lichtheimia strain did
not exhibit the same effect of spore opsonisation upon phagocytosis, with opsonised spores being
phagocytosed to a similar degree as swollen spores, but more frequently than resting spores [22].
The discovery of virulent Lichtheimia spores being phagocytosed to a greater degree than attenuated
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Lichtheimia spores is both interesting and unexpected considering that phagocytosis of pathogens
classically leads to the eradication of pathogenic microorganisms. Whilst it has been postulated that
virulent Mucorales spores may display this phenomenon to utilise the macrophage as a vector for
dissemination, this has yet to be shown.
Little consideration has been given to the lack of spore killing by healthy macrophages and
its relevance in infection to date. In vitro, rabbit bronchoalveolar macrophage fungicidal activity
against Rhizopus oryzae spores depends on the developmental stage of spores [23]. Levitz et al. (1986),
found the greater the swelling and metabolic activity of spores, the greater the efficacy of macrophage
activity against them [23]. In contrast, resting sporangiospores were found to be highly resistant to
macrophage activity [23]. Investigating the influence of macrophage activity against Mucorales
sporangiospores in healthy murine models has also shown that bronchoalveolar macrophages
fail to successfully kill R. oryzae spores, although spore germination is suppressed [24] (Figure 1).
The Drosophila melanogaster model has revealed that the phagocytosis of R. oryzae spores is delayed
compared with that of Aspergillus fumigatus conidia under normal immune status [4]. In addition,
the hyphal damage of R. oryzae is significantly reduced compared with that of A. fumigatus [4].
Collectively, these elucidations indicate that the healthy human host is not wholly effective in killing
resting Mucorales spores. Although reported cases of mucormycosis in immunocompetent hosts are
rare, preliminary revelations that healthy macrophages are incapable of killing Mucorales spores
offers worthy reason for understanding why this is so [25–27]. The classical understanding of
pathogenic clearance appears not to be fully applicable to our understanding of Mucorales clearance,
and highlights the need for enhancing our knowledge of Mucorales–macrophage interactions under
normal immune conditions.
The literature on Mucorales–macrophage interactions under normal vs. immunocompromised
states is limited. However, studies have elucidated differences in macrophage responses to Mucorales
between the two. Survival studies looking at mucormycosis in healthy vs. immunocompromised
model organisms, such as zebrafish and Drosophila, show that immunosuppressive treatment
significantly increases mortality [4,16]. In vivo studies on the effect of immunosuppression upon
macrophage–Mucorales interactions confirm that phagocytic activity is considerably impaired
when compared with their activity under a healthy immune state [4,28]. Cortisone treatment,
rendering murine models immunocompromised, revealed not only the inability of macrophages to
kill R. oryzae spores, but also the failure to inhibit spore germination [28]. Dexamethasone treatment
of Drosophila mimics that of human corticosteroid treatment and results in immunosuppression.
Under such treatment, D. melanogaster displays impaired phagocytic efficacy against R. oryzae
compared with that observed in healthy flies [4]. Moreover, hyphal damage is further reduced
and phagocytosis of Rhizopus spores is void altogether [4].
Understanding mucormycete–macrophage interactions under immunocompetency versus
immunocompromisation is crucial for understanding how Mucorales take advantage of those
with dampened immunity. The inability of macrophages to inhibit Mucorales spore germination
under immunocompromised conditions appears to be, in part, fundamental to the establishment of
mucormycosis. This stark difference in macrophage response to Mucorales, both with regards to
spore developmental stage and morphological form, may elucidate how these opportunistic fungal
pathogens evade macrophage activity and establish disease so aggressively.
2.3. Neutrophil Response to Mucorales
Neutrophils are the most abundant type of leukocytes found in the blood, and are rapidly recruited
to the site of pathogenic infection [29–31]. The ability of these innate immune cells to phagocytose and
destroy pathogens in a non-specific and rapid manner is crucial in combatting pathogenic invasion [31].
Neutrophils not only destroy pathogens via an array of means, such as neutrophil cationic peptides
and oxidative bursts, but also play a key role in mediating acute inflammation and maintaining
haemostasis by infiltrating infected sites and undergoing timely apoptosis [30–32].
J. Fungi 2017, 3, 48 4 of 11
The neutrophil–Mucorales interaction is of great interest when considering mucormycosis,
especially due to its associated risk factor, neutropenia [33,34]. Under healthy immune conditions,
neutrophils are shown not to be readily recruited to resting Mucorales spores in the lungs of intranasally
infected mice [35]. Intranasal inoculation of swollen Rhizopus spores; however, sees a marked
increase in both neutrophil recruitment and inflammation [34]. Moreover, in vitro chemotactic studies
show that swollen Rhizopus spores produce neutrophil chemotactic factors, but resting spores do
not [35]. Neutrophils exhibit fungicidal activity mediated by the production of cationic peptide
activity [36]. As was observed with macrophage activity against Mucorales spores, it was found that
the R. oryzae spore developmental stage influences the efficacy of neutrophil-killing activity.
Neutrophil cationic peptides NP-1 and NP-2 have redundant activity against resting R. oryzae spores;
however, against swollen R. oryzae spores, killing by NP-1 and NP-2 is effective (Figure 1) [24].
Rhizopus hyphae have been shown to induce the expression of tlr2 mRNA in human polymorphonuclear
neutrophils, which indicates that TLR2 contributes as a pattern recognition receptor towards Mucorales
recognition by these leukocytes [37]. Following exposure to Rhizopus hyphae, neutrophil expression of
pro-inflammatory genes such as tnf-α and il-1b is noted, which implies neutrophil activation in response
to Mucorales [37]. Neutrophils are capable of causing R. oryzae hyphal damage, albeit to an attenuated
degree compared with the damage they cause to A. fumigatus hyphae [37,38]. Reduced hyphal damage
to mucormycetes by neutrophils is associated with a dampened oxidative burst, as seen by reduced
superoxide anion release [38].
Hyperglycemia and ketoacidosis both impair phagocytic effector functions [39]. Comparisons drawn
between R. oryzae hyphae treated with normal human serum versus DKA serum indicate the strong
influence of hyperglycaemia and low pH on the killing of Mucorales hyphae by neutrophils [38].
Not only is neutrophil migration to hyphae considerably impaired under hyperglycaemic and ketoacidosis
conditions, effective hyphal killing by these phagocytes is also reduced [38].
The influence of Mucorales spore developmental stage on the efficacy of neutrophil combat under
immunocompetency coincides with that concerning macrophages. Since resting spores are able to
evade neutrophil encounters by bearing negligible chemotactic properties, they have an advantage
over the healthy host. Whilst neutrophils are capable of killing swollen Mucorales spores and hyphae,
the degree of damage and destruction is significantly lower when compared with that of Aspergillus.
This shortfall in neutrophil phagocytic effect is exaggerated further under immunocompromised
conditions such as hyperglycaemia. As neutrophils are one of the early innate immune effectors that
Mucorales are likely to encounter, and as these leukocytes play a key role in acute inflammation,
enhancing our current understanding of Mucorales pathogenesis enabling neutrophil evasion could
prove paramount in combatting disease.
2.4. Endothelial Interaction with Mucorales
Angioinvasion is a hallmark of mucormycosis. Penetration of the endothelial lining of vasculature
results in thrombosis and tissue necrosis, and is the process that enables Mucorales to disseminate
haemotogenously. R. oryzae adheres directly to endothelial cells, and induces injury through
internalisation. Entry to endothelial cells is mediated by the endothelial cell surface receptor GRP78,
the expression of which is greatly enhanced when under DKA and hyperglycaemic conditions [5,19].
Iron chelation therapy in mouse models showed that Rhizopus was unable to successfully invade
endothelial cells, and highlighted that Mucorales internalisation is host iron dependent [19].
2.5. Platelet-Mucorales Interaction
Platelets have been classically affiliated with haemostasis, thrombosis, and inflammation [40]. Recently,
platelets have been identified as key innate immune effectors. These small, anuclear thrombocytes bear
antimicrobial properties that are mediated via granular release of platelet antimicrobial peptides such
as platelet factor 4 (PF-4), as well as display chemotactic properties toward phagocyte recruitment,
mediated via the release of cytokines such as IL-1b [40,41].
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As thrombosis is a hallmark of mucormycosis, the role of platelets in the innate immune response
to Mucorales is of great interest. In vitro studies show that platelets adhere to both Mucorales
spores and hyphae as well as induce platelet activation and granule release [42]. Platelet interaction
significantly inhibits fungal germination, reduces Rhizopus, Mucor, Lichtheimia and Rhizomucor hyphal
growth, and induces hyphal damage (Figure 1) [42].
The ability of platelets to inhibit Mucorales germination suggests that these innate immune effectors
play a beneficial role. Contrarily, excessive thrombosis results in thrombocytopenia, and makes surgical
intervention for diagnosis and treatment undesirable [43]. Whilst preliminary research has identified
that platelets play a direct role in immunity against Mucorales, the underlying mechanisms remain
to be identified. Furthermore, the effects of immunosuppression and immunocompromisation on
platelet–Mucorales interactions have not been divulged.
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stage. Immune effector activity varies depending upon the developmental stage of the Mucorales
sporangiospore. Foll wing the successful crossing of the epithelium, spores encounter in ate immune
effectors such as macrophages and neutrophils. Macrophages suppress resting spore germination; however,
they are unable to kill resting spores. Conversely, swollen Mucorales spores and hyphae are susceptible to
damage and degradation by macrophages. Neutrophil cationic peptides do not exert activity against resting
spores, but induce damage upon swollen spores. Moreover, neutrophil superoxide anion (O2−) release
causes damage to hyphae. Having crossed the endothelium layer by means of hyphal invasion and spore
internalisation, Mucorales invade the vasculature and enter the bloodstream. Herein, Mucorales come into
contact with platelets, whereby platelets adhere to Mucorales spores and hyphae to suppress spore
germination as well as cause hyphal damage.
2.6. Dendritic Cell–Mucorales Interaction
Dendritic cells (DCs) play a pivotal role in the host response to pathogenic invasion by means
of acting as the major antigen-presenting cell for adaptive immune effectors and triggering the
adaptive immune system [44]. In a healthy immune setting and upon pathogen recognition,
DCs phagocytose pathogens, secrete pro-inflammatory cytokines, and present pathogenic antigens to
T and B lymphocytes [45–47].
The DC–Mucorales interaction is less well researched than those of other immune effectors and
mucormycetes. An in vitro study showed that DC activation does not occur in response to Rhizopus
spores; however, hyphae were shown to induce a strong DC release of IL-23, which is known to
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drive Th-17 responses, and TNF-α, which is known to upregulate Th-1 responses (Figure 2) [48,49].
β-glucanase treatment of Rhizopus hyphae showed that the fungal cell wall component β-glucan is
essential for IL-23 production and Th-17 responses by DCs [48]. Furthermore, the inhibition of the DC
β-glucan receptor dectin-1 abolished IL-23 production by DCs, elucidating that DC activation occurs
in response to Mucorales surface β-glucan, and is dectin-1-dependent [48].
Similar to macrophages and neutrophils, the response of DCs differs significantly depending
upon the stage of germination of the Mucorales sporangiospore. Literature is limited regarding
DC–Mucorales interaction; however, it is apparent that healthy DCs fail to recognise resting Mucorales
spores. DCs are key drivers of the adaptive immune response, and thus investigations of DC–Mucorales
interactions should be extended to encompass the effect of immunosuppression on their efficacy.
2.7. Natural Killer Cell Response to Mucorales
Natural killer (NK) cells play a regulatory and cytotoxic role in the innate immune response to
pathogens [50]. Mucorales hyphae penetrate epithelial and endothelial tissue, causing extensive tissue
damage. As natural killer cells are responsible for limiting tissue damage by means of inducing cell
cytoxicity, the role of these lymphocytes in mucormycosis should not be disregarded. NK cell activity
is highly dependent upon signalling from macrophages, DCs, and T cells [50]. Cytokines such as
IL-12 and type-1 interferon (IFN) are potent NK cell activators and mediate the interplay between
macrophages and NK cells, which frequently co-localise at sites of infection and tissue damage.
Whilst traditionally associated with handling tumour cells, NK cells have also been suggested to play
a role in minimising exacerbated macrophage activity during infection [51].
The role of NK cells in mucormycosis is an understudied area of research, yet it has been
shown that Rhizopus spores do not activate NK cells and are resistant to their fungicidal activity [51].
In contrast, Rhizopus hyphae activate NK cells and are damaged by human natural killer cells through
the release of perforin [51]. However, Rhizopus hyphae also exhibit the capacity to suppress secretion of
immunoregulatory molecules by NK cells, such as interferon-γ (IFN-γ) and RANTES, which suggests
that Mucorales hyphae have an immunosuppressive effect upon NK cells [7,51].
3. The Adaptive Immune Response to Mucorales
The adaptive immune system plays a secondary role in handling invasive fungal infections
caused by Mucorales. Initially, T cells were believed to have little significance in the immune response
due to T-cell deficiency bearing no influence on an individual’s risk to Mucorales infection [52].
The implication of DCs inducing Th-17 responses, however, suggests that T-cell responses to
mucormycetes are activated and worthy of investigation.
T-Cell Responses to Mucorales
Th cells are noted to play a key role in the clearance of pathogenic fungi, which is mediated by
the secretion of distinct cytokines [53]. Interferon-γ producing Th-1 cells confer protective immunity
against fungi, whereas Th-2 responses increase susceptibility to fungal infections [53]. Th-17 cells are
named after their robust IL-17 production, and have also been identified and implicated in mucosal
immunity against fungi [53].
In vitro stimulation of T cells by Rhizopus oryzae showed the generation of Th-17 cells [48].
Th-17 cell production of IL-17 has a profound impact on neutrophil activity by acting as
a chemoattractant and inducing the production of antifungal defensins by neutrophils (Figure 2) [53].
Tcyt-cells were not found to be generated against R. oryzae [48].
A study investigating mucormycete-specific T-cells in patients with invasive mucormycosis
found that Mucorales-specific T-cells belonging to both CD4+ and CD8+ subsets were present
during infection. Furthermore, the investigation of Mucorales-specific T-cell cytokine profiles
showed IL-4 (Th-2 cytokine), IFN-γ and IL-10 (Th-1 cytokine) to be most abundantly produced,
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followed by IL-17 [54]. Additionally, IFN-γ producing T-cells were shown to induce Mucorales hyphal
damage (Figure 2) [54].
Research upon T-cell involvement in immunity against Mucorales is sparse, though preliminary
findings highlight the induction of a Th-17 response which may strengthen the neutrophilic attack on
mucormycetes. Conducting in vivo investigations of T-cell responses to Mucorales under healthy and
compromised host immunity would be desirable to enhance our understanding of how T-cells interact
with this fungal pathogen.
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and TNF-α upregulates Th-1 responses. IL-17 production by Th-17 cells aids neutrophil recruitment
and antifungal defensin release, and IFN-γ secretion by Th-1 cells exhibits Mucorales hyphal damage.
4. Conclusions
Invasive fungal infections are increasingly becoming a concern with the rise in fatal cases
seen as of late. Mucormycosis cases have been increasi glob lly, yet he efficacy of current
therapeutics remains unacceptably po r at ar und 60–70%. Understanding the pathogenicity of
invasive fungal infection causing Mucorales is paramount in combatting the high fatality rates
associated with fungi of this order. Mucorales are able to evade pathogenic clearance by the host
immune system and undergo germination within the host, whereby hyphae formation allows for
angioinvasion, dissemination, and irreparable tissue damage. The inability of a compromised host
immune system to suppress Mucorales germination is critical in enabling mucormycetes to establish
infection, which upon widespread dissemination is virtually impossible to resolve.
Mucorales are incredibly efficient at overcoming intact epithelia and endothelia, although the exact
nature of facilitation is unknown. Elucidating the molecular underpinnings of endothelial and epithelial
invasion could prove fruitful in identifying novel drug targets that may cease Mucorales in its tracks before
it encounters the innate immune system.
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The developmental stage of the sporangiospore influences the efficacy of macrophage
phagocystosis and killing upon it, with swollen mucormycete spores being less successful at surviving
the mechanisms of macrophage killing. Moreover, once in its hyphal form, R. oryzae succumbs to
macrophage fungicidal damage. Similar to macrophages, neutrophils and NK cells are redundant in
fungicidal activity against resting Mucorales spores; however, these phagocytes are able to effectively
kill swollen sporangiospores and hyphae alike. Dendritic cells play a crucial role in mediating the
initiation of an adaptive immune response to Mucorales, and their response again differs significantly
depending upon the developmental stage of Mucorales spores. Resting Rhizopus spores fail to induce
robust IL-23 release by DCs, whereas exposure to Rhizopus hyphae sees a dramatic increase in IL-23
and TNF-α production.
The role of the adaptive immune system in response to Mucorales is understudied with respect
to that of the innate immune system. R. oryzae induces a strong Th-17 response that is noted
by the robust secretion of IL-17, which plays a key role in recruiting and initiating neutrophil
responses to R. oryzae. Furthermore, IFN-γ producing T-cells have been shown to damage Mucorales
hyphae. Whilst in vitro study has elucidated the activation of T-cells in response to Mucorales,
the influence of spore developmental stage is not well addressed, and in vivo research is lacking
in the current literature.
Enhancing our understanding of the immune response to Mucoralean fungi is crucial in
identifying how these pathogenic species evade immune defence mechanisms, and improving current
therapeutics for mucormycosis. The delicate differences in Mucorales clearance by immune cells,
as seen between the different developmental stages of Mucorales spores and hyphae, is noteworthy
and indicative of how this fungal pathogen does not succumb to immune clearance.
Author Contributions: Harlene Ghuman and Kerstin Voelz conceived and wrote the manuscript.
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